INBS commences multi-site method comparison study for FDA 510(k) submission

Intelligent Bio Solutions initiated a clinical study with CenExel to validate its Intelligent Fingerprinting Drug Screening System for FDA clearance, with enrollment completion expected by July 2026. The study demonstrates real-world usability by non-specialized personnel, a key competitive advantage for the workplace drug screening market.